ArticleEndocrine2025
Dynapenic abdominal obesity: an important hallmark of metabaging in patients with type 2 diabetes.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to identify high-risk individuals through screening for dynapenic abdominal obesity (DAO) to better mitigate adverse outcomes among type 2 diabetes (T2D) patients in the future.
methodsThis study included 530 middle-aged and older T2D patients. Demographics, nutritional and inflammatory indicators, diabetes-related features, hand grip strength (GS), and body composition were collected. Subjects were grouped by GS and estimated visceral adipose tissue area (eVATA): dynapenia/abdominal obesity (D/AO), nondynapenia/abdominal obesity (N/AO), dynapenia/nonobesity (D/N), and nondynapenia/nonobesity (N/N). Multilevel logistic and linear regression were used to analyze factors influencing DAO and its relationship with vertebral fractures, respectively.
resultsCompared with the N/N group, D/AO group patients were older and had a higher high-sensitivity C-reactive protein (hsCRP) level, homeostasis model assessment of insulin resistance (HOMA-IR), and Diabetes Complications Severity Index (DCSI). Regarding body composition and physical performance, subjects with DAO had a greater percentage of total body fat, a lower ratio of appendicular skeletal muscle mass to weight, a higher lumbar spine T score, and a slower gait speed. The risk factors for DAO included greater age and DCSI. Further regression analysis revealed a positive correlation between DAO and the Spinal Deformity Index (B [95% CI], 0.672 [0.005, 1.339]; P = 0.048).
conclusionsAmong middle-aged and older patients with T2D, DAO is quite common, showing a unique feature related to aging and disease. Identifying DAO may provide new hope for screening high-risk individuals with T2D in terms of functionality and health outcomes.
Indexed as
Identifiers
40908392What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.